A UCLA research team has discovered that creatine, the popular athletic supplement known for building muscle, may also supercharge the immune system's ability to detect and destroy cancer.
The finding, published in iScience, centers on dendritic cells, specialized immune sentries that spot tumors and activate the killer T cells that execute the cancer cells. Researchers found that creatine energizes these dendritic cells, potentially making cancer immunotherapies work for far more patients than currently benefit.
Today's cancer immunotherapies succeed in only about 20 to 40 percent of patients. Lili Yang, the study's senior author and a UCLA professor of microbiology, immunology and molecular genetics, sees creatine as a way to strengthen the entire immune apparatus, not just the T cells doing the final killing.
"Immunotherapy has shown remarkable promise, but it only works for a subset of patients," Yang said. "What this study shows is that creatine doesn't just help the T cells fighting cancer, it also energizes the entire infrastructure that supports and guides them."
The research began with a close look at how dendritic cells behave inside tumors. Scientists examined gene activity in tumor-infiltrating dendritic cells from mice and discovered that the gene controlling creatine transport into cells ran at unusually high levels in these tumor-fighting cells compared to dendritic cells in healthy tissue.
When the team engineered dendritic cells unable to receive creatine, the impact was dramatic. These creatine-deprived cells struggled to survive, became sluggish, and proved far less effective at preparing T cells to recognize and eliminate tumors. In lab dishes, T cells grown alongside these compromised dendritic cells multiplied more slowly and produced fewer chemical signals needed for effective anti-cancer response.
The researchers flipped the experiment to test the opposite scenario. They gave mice with melanoma daily creatine injections and watched tumor growth slow significantly. Dendritic cells that infiltrated the tumors increased in both number and activity. These energized cells also pumped out higher levels of chemical messengers that attracted additional immune reinforcements into the tumor.
Using advanced metabolic analysis, scientists determined that creatine supplementation raised levels of ATP, the cellular energy currency, inside dendritic cells. ATP drives nearly every biological process, and by boosting these energy reserves, creatine maintained the inflammatory signaling pathways needed to keep dendritic cells active and functioning even as they competed with aggressively growing tumor cells for scarce nutrients.
The mechanism resembled a rechargeable battery, allowing dendritic cells to store and deploy energy as circumstances demanded. This energy advantage proved crucial in the nutrient-starved tumor microenvironment.
The team also tested creatine on human immune cells grown in the laboratory. Creatine enhanced the activation of human monocyte-derived dendritic cells, the cells used to manufacture dendritic cell cancer vaccines. The supplement also strengthened those cells' capacity to spur human T cells against cancer-associated targets.
Co-first author James Elsten-Brown, a graduate student in Yang's lab, identified two potential applications. Creatine could serve as a supplement for patients already receiving immunotherapy to amplify their immune response, or it could be incorporated during dendritic cell vaccine production to boost vaccine effectiveness before administration.
The results point to a strategy that fortifies the immune system's anti-cancer defenses at multiple checkpoints, beginning with the cells that first detect malignancies and trigger the body's response.
Researchers stress that the work remains preliminary. All experiments occurred in mice or human cells cultured in laboratory conditions, not in cancer patients. Results should not be interpreted as proof that creatine supplements improve cancer outcomes in living people.
While creatine monohydrate has been in widespread use for decades and is generally safe at recommended doses, scientists emphasize that anyone undergoing cancer treatment must consult their physician before starting any supplement regimen.
The next phase requires prospective clinical trials to determine whether creatine supplementation actually improves outcomes for patients receiving cancer immunotherapy. The experimental methods described have not been tested in humans or approved by the FDA as safe and effective for human use.
Author Jessica Williams: "The leap from lab mouse to human patient is vast, but early data showing creatine energizes the immune system's tumor-fighting machinery at multiple levels is worth pursuing in clinical trials."
Comments